Polymorphism of CYP2D6 and NQO1 in children with acute lymphoblastic leukemia

Pediatric Hematology/Oncology and Immunopathology

Volumn 1, Issue 1, 2002, Pages 52-59

  Maiorova, O A ^a   Mogl, M T ^b   Henze, G ^b   Seeger, K ^b   Rumyantsev, A G ^a  

^a Russian Federation Health Ministry   (Russian Federation)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

ALL; Children; CYP2D6; Cytochrome P450; Genetic polymorphism; NQO1

Indexed keywords

EID: 44349083270     PISSN: 17261708     EISSN: 24149314     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Aynacioglu A., Sachse C., Bozkurt A. et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 1999; 66: 185–192.
2. Chen H., Lum A., Seifried A. et al. Association of the NAD(P)H:quinone oxidore-ductase 609 C T polymorphism with a decreased cancer risk. Cancer Res. 1999; 59: 3045–3048.
3. Clairmont A., Sies H., Ramachandran S. et al. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a mul-tivariative model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 1999; 20: 1235–1240.
4. Dunning A., Healey C., Pharoah P. et al. A systematic review of genetic polymor-phisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 843–854.
5. Gaedigk A., Tyndale R., Jurima-Romet M. et al. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequences in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 1998; 8: 305–313.
6. Garcia-Barcelo M., Chow L., Chui H.F.K. et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin.Chem. 2000; 46: 18–23.
7. Gonzalez M., Alvarez V., Pello M. et al. Genetic polymorphism of N-acetyltrans-ferase-2, gluthatione S-transferase-M1, and cytochromes P450IIE1 in the susceptibility to head and neck cancer. J.Clin.Pathol. 1998; 51: 294–298.
8. Griese E., Asante-Poku S., Ofori-Adjei D. et al. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999; 9: 715–723.
9. Gustafsson L., Eriksson L., Dahl M. et al. Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a casual relationship? J. Intern. Med. 1996; 240: 311–314.
10. Hasler J., Estabrook R., Murray M. et al. Human cytochromes P450. Mol. Asp. Med. 1999; 20: 1–137.
11. Joseph P., Jaiswal A. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenic-ity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones. Br. J. Cancer 1998; 77: 709–719.
12. Krajinovic M., Labuda D., Richer C. et al. Susceptibility to childhood acute lym-phoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999; 93: 1496–1501.
13. Larson R., Wang Y., Banerjee M. et al. Prevalence of the inactivating 609 С→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Ibid. 94: 803–807.
14. Lemos M., Cabrita F. et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999; 20: 1225–1229.
15. Li D., Pritchard M., Hanlon S. et al. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. J. Pharmacol. Exp. Ther. 1999; 289: 661–667.
16. Marez D., Legrand M., Sabbagh N. et al. Polymorphism of the cytochrome P450 2D6 gene in a European population: characterization of 48 mutations and 53 alle-les, their frequences and evolution. Pharmacogenetics 1997; 7: 193–202.
17. Marsh J., Chowdry J., Parry-Jones N. et al. Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anemia. Br. J. Haematol. 1999; 104: 266–270.
18. Moran J., Siegel D., Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc. Natl. Acad. Sci. USA 1999; 96: 8150–8155.
19. Nebert D. Polymorphisms in drug-metabolizing enzymes: what is their clinical rel-evance and why do they exist. Am. J. Clin. Genet. 1997; 60: 265–271.
20. Okamura T., Kurisu K., Yamamoto W. et al. NADPH/quinone oxidireductase is a priority target of glioblastoma chemotherapy. Int.J.Oncol. 2000; 16: 295–303.
21. Rothman N., Smith M., Hayes R. et al. Benzene poisoning, a risk factor for hema-tological malignancy, is associated with the NQO1 609 C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997; 57: 2839–2842.
22. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequences and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 284–295.
23. Schulz W., Krummeck A., Rosinger I. et al. Increased frequency of a null-allele for NAD(P)H:qunone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997; 7: 235–239.
24. Seeger K, Adams H., Buchwald D. et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. Blood 1998; 91: 1716–1722.
25. Traver R., Siegel D., Beall H. et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 1997; 75: 69–75.
26. Wiemels J., Pagnamenta A., Taylor G. et al. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res. 1999; 59: 4095–4099.